Figure 2.

Changes from baseline to interim evaluation and last visit in secondary outcomes (peripheral markers). Panel A shows changes in serum concentrations of SHBG between baseline and last available follow-up visit on treatment with Triac (n = 47). Panel B shows the change in serum SHBG concentrations from baseline to 1 year and last available visit (longitudinal within-subject analyses; n = 22). Panel C shows changes in serum concentrations of creatinine between baseline and last available follow-up visit on treatment with Triac (n = 46). Panel D shows the change in serum creatinine concentrations from baseline to 1 year and last available visit (longitudinal within-subject analyses; n = 19). Panel E shows changes in serum concentrations of CK between baseline and last available follow-up visit on treatment with Triac (n = 46). Panel F shows the change in serum CK concentrations from baseline to 1 year and last available visit (longitudinal within-subject analyses; n = 19; for clarity, data are depicted as nontransformed in panels E and F). Median treatment duration was 2.2 years (interquartile range [IQR] 1.5–3.9 years) for analyses of secondary outcomes (panels A, C, and E) and 3.6 years (IQR 2.5–5.2 years) for longitudinal within-subject analyses (panels B, D, and F). Black dashed lines represent the reference intervals (for the median baseline age). Black dots represent baseline measurement and gray arrows represent the last available measurement in panels A, C, and E. Gray dots represent measurements in the individual patients in panels B, D, and F; means and standard error of the mean are displayed in blue. Abbreviations: CK, creatine kinase; SHBG, sex hormone-binding globulin.